Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2010 - 2026)

Jazz Pharmaceuticals has reported Non-Current Debt for 16 years, with the latest figure at $4.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 18.97% year-over-year to $4.3 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (down 18.97% YoY), and the FY2025 full-year result was $4.3 billion, down 28.78% from the prior year.
• Non-Current Debt for Q1 2026 stood at $4.3 billion, roughly flat from $4.3 billion in the prior quarter.
• The five-year high for Non-Current Debt was $6.1 billion in Q3 2024, with the low at $4.3 billion in Q1 2026.
• Average Non-Current Debt over 5 years is $5.3 billion, with a median of $5.3 billion recorded in 2025.
• Year-over-year, Non-Current Debt jumped 223.41% in 2022 and fell 28.78% in 2025.
• Tracing JAZZ's Non-Current Debt over 5 years: stood at $5.7 billion in 2022, then dropped by 10.28% to $5.1 billion in 2023, then climbed by 18.98% to $6.1 billion in 2024, then decreased by 28.78% to $4.3 billion in 2025, then decreased by 0.1% to $4.3 billion in 2026.
• The last three Non-Current Debt figures came in at $4.3 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.

Peer Comparison